CVS Health Co. (NYSE:CVS) Stake Increased by Capital International Sarl

Capital International Sarl increased its holdings in shares of CVS Health Co. (NYSE:CVS) by 75.6% during the fourth quarter, HoldingsChannel.com reports. The institutional investor owned 47,151 shares of the pharmacy operator’s stock after purchasing an additional 20,306 shares during the quarter. Capital International Sarl’s holdings in CVS Health were worth $2,117,000 as of its most recent SEC filing.

Several other large investors have also recently bought and sold shares of the business. CANADA LIFE ASSURANCE Co boosted its holdings in shares of CVS Health by 3.4% during the fourth quarter. CANADA LIFE ASSURANCE Co now owns 2,115,154 shares of the pharmacy operator’s stock worth $94,890,000 after purchasing an additional 69,641 shares during the period. Strategic Investment Solutions Inc. IL boosted its stake in shares of CVS Health by 77.2% during the 4th quarter. Strategic Investment Solutions Inc. IL now owns 1,024 shares of the pharmacy operator’s stock valued at $46,000 after buying an additional 446 shares during the period. MSH Capital Advisors LLC purchased a new position in shares of CVS Health during the 4th quarter valued at $218,000. Dodge & Cox raised its holdings in shares of CVS Health by 11.2% during the fourth quarter. Dodge & Cox now owns 70,105,899 shares of the pharmacy operator’s stock worth $3,147,054,000 after acquiring an additional 7,075,209 shares in the last quarter. Finally, Jump Financial LLC boosted its position in CVS Health by 3,329.0% during the fourth quarter. Jump Financial LLC now owns 342,903 shares of the pharmacy operator’s stock valued at $15,393,000 after purchasing an additional 332,903 shares during the last quarter. 80.66% of the stock is owned by institutional investors and hedge funds.

Insider Activity

In other CVS Health news, Director Michael F. Mahoney purchased 30,000 shares of the firm’s stock in a transaction on Tuesday, February 18th. The shares were purchased at an average price of $66.70 per share, for a total transaction of $2,001,000.00. Following the completion of the purchase, the director now directly owns 39,356 shares of the company’s stock, valued at approximately $2,625,045.20. This represents a 320.65 % increase in their ownership of the stock. The acquisition was disclosed in a document filed with the Securities & Exchange Commission, which is accessible through this hyperlink. Also, SVP James David Clark sold 7,513 shares of CVS Health stock in a transaction dated Wednesday, March 5th. The shares were sold at an average price of $66.35, for a total transaction of $498,487.55. Following the sale, the senior vice president now owns 8,394 shares in the company, valued at approximately $556,941.90. This trade represents a 47.23 % decrease in their ownership of the stock. The disclosure for this sale can be found here. 0.24% of the stock is currently owned by company insiders.

Wall Street Analyst Weigh In

A number of equities research analysts have recently weighed in on CVS shares. Leerink Partnrs raised CVS Health from a “hold” rating to a “strong-buy” rating in a research note on Wednesday, February 12th. Morgan Stanley reaffirmed an “overweight” rating on shares of CVS Health in a research report on Tuesday. Piper Sandler increased their price target on shares of CVS Health from $72.00 to $74.00 and gave the stock an “overweight” rating in a research note on Friday, March 21st. Barclays lifted their price objective on shares of CVS Health from $71.00 to $73.00 and gave the company an “overweight” rating in a research note on Thursday, February 13th. Finally, Wells Fargo & Company increased their target price on shares of CVS Health from $68.00 to $73.00 and gave the stock an “overweight” rating in a research report on Thursday, February 13th. Four analysts have rated the stock with a hold rating, eighteen have assigned a buy rating and one has issued a strong buy rating to the company’s stock. According to MarketBeat.com, the stock currently has a consensus rating of “Moderate Buy” and a consensus price target of $71.83.

CVS Health Stock Down 2.0 %

CVS opened at $67.19 on Friday. CVS Health Co. has a 1-year low of $43.56 and a 1-year high of $71.45. The business has a 50 day moving average of $66.46 and a 200-day moving average of $58.79. The stock has a market capitalization of $84.71 billion, a price-to-earnings ratio of 18.36, a P/E/G ratio of 0.98 and a beta of 0.57. The company has a current ratio of 0.81, a quick ratio of 0.60 and a debt-to-equity ratio of 0.80.

CVS Health (NYSE:CVS) last posted its quarterly earnings results on Wednesday, February 12th. The pharmacy operator reported $1.19 earnings per share (EPS) for the quarter, topping the consensus estimate of $0.89 by $0.30. CVS Health had a net margin of 1.24% and a return on equity of 9.11%. As a group, sell-side analysts anticipate that CVS Health Co. will post 5.89 earnings per share for the current year.

CVS Health Dividend Announcement

The company also recently disclosed a quarterly dividend, which will be paid on Thursday, May 1st. Shareholders of record on Tuesday, April 22nd will be given a $0.665 dividend. The ex-dividend date is Tuesday, April 22nd. This represents a $2.66 dividend on an annualized basis and a dividend yield of 3.96%. CVS Health’s dividend payout ratio is currently 72.68%.

CVS Health Company Profile

CVS Health Corporation provides health solutions in the United States. It operates through Health Care Benefits, Health Services, and Pharmacy & Consumer Wellness segments. The Health Care Benefits segment offers traditional, voluntary, and consumer-directed health insurance products and related services.